Kyverna Therapeutics Q3 2026 Results: Net Loss of $41.9M, Loss Widens
Kyverna Therapeutics reported a net loss of $119.99 million for the nine months ended September 30, 2026, compared to $123.50 million in the prior year period. The company's cash and marketable securities position decreased to $170.57 million as of September 30, 2026, down from $279.25 million at the end of 2025, primarily due to ongoing research and development expenses.
- Key figure
- Net loss $41.9M